You are here: Industry Insights > Bi

News List

Introduction of Ubiquicidin (29–41) as an Emerging Infection Imaging Agent Sadia Ajmal
September 28, 2025
The diagnosis of infectious diseases continues to challenge clinicians, particularly when it comes to distinguishing active infection from sterile inflammation or malignant processes.
Digitalization in Procurement: From AI Forecasting to Blockchain Traceability Saher Haider
September 19, 2025
Over the last couple of years, AI and blockchain have made inroads into the life sciences industry, including the pharmaceutical supply chain network.
The Rise of Biosimilars: Regulatory Pathways and Market Outlook Nurah Ekhlaque
September 19, 2025
Biosimilars are changing the way healthcare systems manage the high cost of advanced medicines.
Basic Concepts and Latest Trends in Radiation Biology: Emerging Insights and Future Directions Sadia Ajmal
September 18, 2025
This article outlines the basic concepts of radiation biology—including types of radiation, mechanisms of DNA damage, repair pathways, and biological outcomes—followed by a synthesis of the latest trends shaping the field.
Made-in-China New Drugs: The Game and Breakthrough in the Over - 4 - Billion Market Lezhi
September 05, 2025
Profiles 16 China-made blockbuster drugs exceeding ¥1B sales, highlighting intense PD-1 competition, EGFR tech innovation, and bispecific antibody/non-oncology surge.
Made-in-China New Drugs: Breaking Through the RMB 4-Billion Battlefield lezhi
September 05, 2025
In 2024, the "Billion-Yuan Club" of made-in-China first-in-class new drugs expanded to 16 members.
Drug-Device Combination Products: Making a Step Towards Better Adherence Suzanne Elvidge
August 01, 2025
More than half of the world’s population takes at least one medication daily, but the safety and efficacy data from clinical trials isn’t always fully reflected in real world use.
Predicted Top 5 Worldwide Selling Generic or Biosimilar Drugs in 2025 David Orchard-Webb
July 08, 2025
The global pharmaceutical market is approaching a phase in which several high-revenue medicines will lose patent protection, paving the way for generic and biosimilar competition (Scheckel, 2021).
The Bitter Medicine is Good for Health: Research Progress on the Components and Pharmacological Activities of Coptis Chinensis Xiaomichong
July 02, 2025
Coptis chinensis, a perennial herbaceous plant of the Ranunculaceae family, is also known as "Wei Lian," "Yun Lian," "Ya Lian," "Ji Zhuazhao Lian," and so on.
Global API Sourcing Trends: Why Quality Antibiotics Matter in 2025 Saher Haider
August 22, 2025
Quality antibiotic APIs are critical to combat antimicrobial resistance (AMR). Global buyers prioritize GMP-compliant suppliers (notably Chinese exporters) for resilient sourcing amid regulatory and ESG pressures in 2025.